Zoetis Inc. $ZTS Shares Sold by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,247 shares of the company’s stock after selling 5,771 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Zoetis were worth $25,926,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Nuveen LLC purchased a new position in shares of Zoetis in the first quarter valued at $616,375,000. Mackenzie Financial Corp boosted its stake in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the period. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Amundi boosted its stake in shares of Zoetis by 30.8% in the first quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in shares of Zoetis by 33.5% in the first quarter. Pictet Asset Management Holding SA now owns 2,671,742 shares of the company’s stock valued at $439,851,000 after purchasing an additional 670,459 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.2%

Zoetis stock opened at $146.14 on Monday. The firm’s 50-day moving average is $148.18 and its 200-day moving average is $153.57. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $184.40. The company has a market cap of $64.77 billion, a P/E ratio of 25.15, a PEG ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the firm posted $1.56 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Analysts Set New Price Targets

ZTS has been the subject of several analyst reports. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Friday. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus reiterated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Finally, UBS Group reduced their price objective on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday, October 20th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.